PFS with ixazomib vs placebo according to MRD status at randomization. Kaplan-Meier analysis of PFS for patients with MRD⁺ or MRD⁻ status at randomization who received ixazomib or placebo in the TOURMALINE-MM3 and -MM4 trials. NR, not reached.